Angiogenesis Pathway

Angiogenesis Pathway

Introduction

Angiogenesis is the process of forming new blood vessels from existing ones, critical for brain function and heavily implicated in neurodegenerative diseases. This pathway regulates cerebral blood flow, blood-brain barrier maintenance, and neurovascular coupling—all essential for neuronal health and function. [@greenberg2005]

In the adult brain, angiogenesis is tightly regulated under normal conditions but becomes dysregulated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, coordinates angiogenic processes essential for brain homeostasis. [@ruiter2013]

Overview

| Property | Value | [@zlacany2020]
|----------|-------| [@plate2019]
| Process | New blood vessel formation from existing vasculature | [@baldwin2018]
| Primary Regulator | Vascular Endothelial Growth Factor (VEGF) | [@tachibana2021]
| Adult Brain Status | Limited under normal conditions; reactivated in pathology | [@iadecola2017]
| Key Cell Types | Endothelial cells, pericytes, vascular smooth muscle cells, astrocytes | [@winkler2014]
| Brain Regions Affected | Cortex, hippocampus, substantia nigra, basal ganglia | [@sagare2013]

Molecular Pathway

VEGF Signaling Cascade

The VEGF signaling pathway is the primary driver of angiogenesis in the brain: [@wang2022]

Angiogenesis Pathway

Introduction

Angiogenesis is the process of forming new blood vessels from existing ones, critical for brain function and heavily implicated in neurodegenerative diseases. This pathway regulates cerebral blood flow, blood-brain barrier maintenance, and neurovascular coupling—all essential for neuronal health and function. [@greenberg2005]

In the adult brain, angiogenesis is tightly regulated under normal conditions but becomes dysregulated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, coordinates angiogenic processes essential for brain homeostasis. [@ruiter2013]

Overview

| Property | Value | [@zlacany2020]
|----------|-------| [@plate2019]
| Process | New blood vessel formation from existing vasculature | [@baldwin2018]
| Primary Regulator | Vascular Endothelial Growth Factor (VEGF) | [@tachibana2021]
| Adult Brain Status | Limited under normal conditions; reactivated in pathology | [@iadecola2017]
| Key Cell Types | Endothelial cells, pericytes, vascular smooth muscle cells, astrocytes | [@winkler2014]
| Brain Regions Affected | Cortex, hippocampus, substantia nigra, basal ganglia | [@sagare2013]

Molecular Pathway

VEGF Signaling Cascade

The VEGF signaling pathway is the primary driver of angiogenesis in the brain: [@wang2022]

• PI3K/AKT Pathway - Mediates endothelial cell survival, nitric oxide production, and vascular permeability
• MAPK/ERK Pathway - Drives endothelial cell proliferation and differentiation
• Src Pathway - Regulates vascular permeability and cytoskeletal reorganization
• FAK Pathway - Controls cell adhesion, migration, and vessel maturation

Key Molecular Players

| Factor | Function | Therapeutic Target |
|--------|----------|-------------------|
| VEGF-A | Primary angiogenic factor, neuroprotection | ✓ |
| VEGF-B | Vessel survival, fatty acid transport | |
| VEGF-C | Lymphangiogenesis | |
| VEGFR2 (KDR/Flk-1) | Main signaling receptor on endothelium | ✓ |
| VEGFR1 (Flt-1) | Decoy receptor, modulates VEGF activity | |
| Ang-1 (Angiopoietin-1) | Vessel stabilization, tight junction maintenance | |
| Ang-2 (Angiopoietin-2) | Vessel destabilization (context-dependent) | |
| Tie2 | Angiopoietin receptor, regulates vascular stability | |
| PDGF-B | Pericyte recruitment and vessel maturation | ✓ |
| TGF-β | Vessel stabilization, extracellular matrix production | |
| Endoglin (CD105) | TGF-β co-receptor, endothelial cell proliferation | ✓ |
| EphrinB2 | Venous/arterial specification | |

VEGF Isoforms and Brain Distribution

The VEGF family includes multiple isoforms with distinct functions:

| Isoform | Key Features | Brain Expression |
|---------|--------------|------------------|
| VEGF-A | Primary angiogenic factor, neuroprotective | Neurons, astrocytes, microglia |
| VEGF-B | Vessel survival, fatty acid metabolism | Lower expression, endothelial cells |
| VEGF-C | Lymphangiogenesis | Limited in brain parenchyma |
| VEGF-D | Similar to VEGF-C | Rare in brain |
| PlGF (PLGF) | Synergizes with VEGF, inflammatory angiogenesis | Induced in pathology |

VEGF-A further splices into VEGF121, VEGF165, and VEGF189 variants:

• VEGF121: Freely diffusible, minimal heparin binding
• VEGF165 (most common): Balanced between diffusible and heparin-bound
• VEGF189: Predominantly cell-associated, highest heparin binding

Role in Neurodegeneration

Alzheimer's Disease

Angiogenesis and vascular dysfunction play critical roles in Alzheimer's disease pathology:

Vascular Hypoperfusion

• Reduced cerebral blood flow (CBF) observed in early AD
• Contributes to amyloid-beta (Aβ) clearance impairment
• Neuronal hypoxia promotes Aβ production via HIF-1α
• White matter lesions from chronic hypoperfusion

• Aβ directly inhibits VEGF signaling
• Aβ induces endothelial cell dysfunction
• VEGF counteracts Aβ-induced neurotoxicity (protective)
• Therapeutic angle: balance VEGF signaling

• Some neovascularization may be beneficial (improved perfusion)
• Pathological angiogenesis can increase BBB permeability
• Cerebral amyloid angiopathy (CAA) involves vessel damage
• Need for precise temporal/spatial targeting

• Pericyte loss in AD brains (correlation with cognitive decline)
• BBB breakdown increases Aβ deposition
• Astrocyte endfoot degeneration disrupts neurovascular coupling
• Reduced coverage of endothelial cells by pericytes

Parkinson's Disease

Vascular contributions to Parkinson's disease include:

Cerebral Blood Flow Alterations

• Reduced CBF in frontal cortex and substantia nigra
• Vascular rarefaction in substantia nigra pars compacta
• Correlation between vascular risk factors and PD severity

• Elevated VEGF in PD CSF (compensatory?)
• Impaired VEGF signaling in substantia nigra
• VEGF neuroprotection studies in animal models

• Increased BBB permeability in PD
• Altered pericyte function
• Leukocyte infiltration in substantia nigra

Other Neurodegenerative Conditions

Vascular Cognitive Impairment (VCI)

• Second most common cause of dementia
• Multi-infarct dementia from multiple small vessel strokes
• Binswanger's disease (subcortical leukoaraiosis)
• Mixed AD/VCI pathology common

• Motor cortex hypoperfusion
• VEGF dysregulation in ALS patients
• SOD1 mice show impaired VEGF signaling
• Clinical trials of VEGF gene therapy

• Reduced cerebral blood flow
• VEGF-A expression changes
• Angiogenic factor alterations in HD models

Mermaid Diagram

Therapeutic Targeting

VEGF-Based Therapies

| Agent | Mechanism | Phase | Indication | Status |
|-------|-----------|-------|------------|--------|
| Bevacizumab | Anti-VEGF monoclonal antibody | Phase 2 | AD | Completed |
| Aflibercept | VEGF trap (VEGFR1/2-Fc) | Phase 1 | AD | Completed |
| VEGF-A gene therapy (Cerebral) | AAV-VEGF delivery | Phase 1 | PD | Completed |
| Ranibizumab | Anti-VEGF Fab fragment | Preclinical | AD/PD | Research |

VEGF-Independent Angiogenesis Pathways

| Pathway | Key Players | Therapeutic Potential |
|---------|-------------|----------------------|
| FGF/FGFR | FGF-2, FGFR1-4 | Agonists in development |
| Angiopoietin/Tie | Ang-1, Ang-2, Tie2 | Agonists being explored |
| Ephrin/Eph | EphrinB2, EphB2 | Under investigation |
| PDGF/PDGFR | PDGF-B, PDGFR-β | Pericyte stabilization |
| Notch/DLL4 | Notch1, DLL4 | Anti-DLL4 antibodies |

Novel Therapeutic Approaches

Combination Therapies

• VEGF therapy + anti-amyloid approaches
• Angiopoietin-1 mimetics for vessel stabilization
• Pericyte-targeting compounds

• Small molecule VEGFR inhibitors
• Peptide-based VEGF modulators
• Cell-penetrant VEGF receptor agonists

• AAV-mediated VEGF expression
• CRISPR-based VEGF regulation
• Ex vivo endothelial cell modification

Clinical Trials

| Trial | Intervention | Phase | Status | Outcome |
|-------|--------------|-------|--------|---------|
| NCT01054235 | Bevacizumab | Phase 2 | Completed | Mixed results |
| NCT01638351 | Aflibercept | Phase 1 | Completed | Safety established |
| NCT00877253 | VEGF gene therapy | Phase 1 | Completed | Safety, some efficacy |
| NCT00733390 | Ranibizumab | Phase 2 | Completed | No cognitive benefit |

Biomarkers Related to Angiogenesis

| Biomarker | Source | Clinical Utility |
|-----------|--------|------------------|
| VEGF-A | Serum, CSF | Disease progression marker |
| sVEGFR1 | Serum | Biomarker for vascular dysfunction |
| sVEGFR2 | Serum | Endothelial function marker |
| PlGF | Serum, CSF | Pathological angiogenesis |
| Ang-2 | Serum, CSF | Vessel instability marker |
| sTie2 | Serum | Soluble receptor, disease activity |
| Endoglin | Serum | Endothelial activation |
| VEGF-C | CSF | Lymphatic/vascular dysfunction |

Background

The study of Angiogenesis Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Cross-References

Related Mechanisms

• Neurovascular Unit
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• Cerebral Hypoperfusion
• Amyloid Cascade
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

Related Proteins

• VEGF Protein
• VEGFR2 Protein
• Ang-1 Protein
• Ang-2 Protein
• Tie2 Protein
• PDGF-B Protein

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Vascular Dementia](/diseases/vascular-dementia)
• Vascular Cognitive Impairment
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

Related Cell Types

• Endothelial Cells
• Pericytes
• [Astrocytes](/cell-types/astrocytes)
• Neural Stem Cells

Recent Research Updates (2024-2026)

Recent publications:

See Also

• [Blood-Brain Barrier](/entities/blood-brain-barrier)
• [Neurovascular Unit](/mechanisms/neurovascular-unit)
• [VEGF Protein](/proteins/vegf-protein)
• [Cerebral Hypoperfusion](/mechanisms/cerebral-hypoperfusion)
• [Alzheimer's Disease Mechanisms](/mechanisms/alzheimers-disease-mechanisms)
• [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-disease-mechanisms)
• [Vascular Dementia](/diseases/vascular-dementia)

Pathway Diagram

The following diagram shows the key molecular relationships involving Angiogenesis Pathway discovered through SciDEX knowledge graph analysis: